DK2051710T3 - Sammensætninger og fremgangsmåder til behandling, reducering, forbedring eller lindring af sygdomme i det bageste øjensegment - Google Patents

Sammensætninger og fremgangsmåder til behandling, reducering, forbedring eller lindring af sygdomme i det bageste øjensegment

Info

Publication number
DK2051710T3
DK2051710T3 DK07813637.1T DK07813637T DK2051710T3 DK 2051710 T3 DK2051710 T3 DK 2051710T3 DK 07813637 T DK07813637 T DK 07813637T DK 2051710 T3 DK2051710 T3 DK 2051710T3
Authority
DK
Denmark
Prior art keywords
compositions
treatment
disorders
relief
improvement
Prior art date
Application number
DK07813637.1T
Other languages
English (en)
Inventor
Raili Kerppola
Gary Phillips
Keith Wayne Ward
Zhenze Hu
Original Assignee
Bausch & Lomb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bausch & Lomb filed Critical Bausch & Lomb
Application granted granted Critical
Publication of DK2051710T3 publication Critical patent/DK2051710T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK07813637.1T 2006-08-07 2007-08-01 Sammensætninger og fremgangsmåder til behandling, reducering, forbedring eller lindring af sygdomme i det bageste øjensegment DK2051710T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83607806P 2006-08-07 2006-08-07
PCT/US2007/074943 WO2008021729A2 (en) 2006-08-07 2007-08-01 Compositions and methods for treating, reducing, ameliorating, or alleviating posterior-segment ophthalmic diseases

Publications (1)

Publication Number Publication Date
DK2051710T3 true DK2051710T3 (da) 2012-02-20

Family

ID=38823645

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07813637.1T DK2051710T3 (da) 2006-08-07 2007-08-01 Sammensætninger og fremgangsmåder til behandling, reducering, forbedring eller lindring af sygdomme i det bageste øjensegment

Country Status (19)

Country Link
US (1) US20080031884A1 (da)
EP (1) EP2051710B1 (da)
JP (1) JP2010500364A (da)
KR (1) KR20090051076A (da)
CN (1) CN101522187A (da)
AT (1) ATE531366T1 (da)
AU (1) AU2007284176B2 (da)
BR (1) BRPI0714817A2 (da)
CA (1) CA2660167C (da)
CY (1) CY1112269T1 (da)
DK (1) DK2051710T3 (da)
ES (1) ES2373999T3 (da)
HK (1) HK1127556A1 (da)
MX (1) MX2009001333A (da)
PL (1) PL2051710T3 (da)
PT (1) PT2051710E (da)
SI (1) SI2051710T1 (da)
TW (1) TWI378928B (da)
WO (1) WO2008021729A2 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101528208A (zh) * 2006-08-31 2009-09-09 博士伦公司 治疗或预防青光眼或其进展的组合物和方法
US20090042936A1 (en) * 2007-08-10 2009-02-12 Ward Keith W Compositions and Methods for Treating or Controlling Anterior-Segment Inflammation
ES2402321T3 (es) * 2007-11-05 2013-04-30 Bausch & Lomb Incorporated Materiales inmiscibles en agua como vehículos para el suministro de fármacos
US20090239836A1 (en) * 2008-03-24 2009-09-24 Mary Lee Ciolkowski Multifunctional Ophthalmic Compositions
US20100008993A1 (en) * 2008-07-14 2010-01-14 Proksch Joel W Compositions and Methods for Increasing Bioavailability of Topical Ophthalmic Drugs
US20110077270A1 (en) * 2009-04-21 2011-03-31 Pfeffer Bruce A Compositions and Methods for Treating Ocular Inflammation with Lower Risk of Increased Intraocular Pressure
US20110189174A1 (en) * 2010-02-01 2011-08-04 Afshin Shafiee Compositions and methods for treating, reducing, ameliorating, alleviating, or inhibiting progression of, pathogenic ocular neovascularization
RU2559585C2 (ru) * 2013-12-26 2015-08-10 Федеральное бюджетное учреждение науки "Уфимский научно-исследовательский институт медицины труда и экологии человека" Способ диагностики раннего воздействия вредных производственных факторов на организм работников, занятых в производстве синтетических смол не более 5 лет
WO2020152193A1 (en) 2019-01-22 2020-07-30 Akribes Biomedical Gmbh Selective glucocorticoid receptor modifiers for treating impaired skin wound healing

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4580559A (en) * 1984-07-24 1986-04-08 Esperance Francis A L Indirect ophthalmoscopic photocoagulation delivery system for retinal surgery
WO2000000194A1 (en) * 1998-06-27 2000-01-06 Photogenesis, Inc. Ophthalmic uses of ppargamma agonists and ppargamma antagonists
US20040121014A1 (en) * 1999-03-22 2004-06-24 Control Delivery Systems, Inc. Method for treating and/or preventing retinal diseases with sustained release corticosteroids
EP1521733B1 (en) * 2002-07-08 2014-08-20 Pfizer Products Inc. Modulators of the glucocorticoid receptor
US7235662B2 (en) * 2003-06-11 2007-06-26 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
DE102004055633A1 (de) * 2004-11-12 2006-05-18 Schering Ag 5-substituierte Chinolin- und Isochinolin-Derivate, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer

Also Published As

Publication number Publication date
BRPI0714817A2 (pt) 2013-05-21
AU2007284176B2 (en) 2013-03-28
CA2660167C (en) 2012-04-10
KR20090051076A (ko) 2009-05-20
WO2008021729A3 (en) 2008-10-09
HK1127556A1 (en) 2009-10-02
CA2660167A1 (en) 2008-02-21
PT2051710E (pt) 2012-02-08
PL2051710T3 (pl) 2012-03-30
CY1112269T1 (el) 2015-12-09
CN101522187A (zh) 2009-09-02
WO2008021729A2 (en) 2008-02-21
JP2010500364A (ja) 2010-01-07
EP2051710A2 (en) 2009-04-29
ES2373999T3 (es) 2012-02-10
US20080031884A1 (en) 2008-02-07
MX2009001333A (es) 2009-02-13
AU2007284176A1 (en) 2008-02-21
TWI378928B (en) 2012-12-11
TW200815416A (en) 2008-04-01
ATE531366T1 (de) 2011-11-15
SI2051710T1 (sl) 2012-02-29
EP2051710B1 (en) 2011-11-02

Similar Documents

Publication Publication Date Title
DK2051710T3 (da) Sammensætninger og fremgangsmåder til behandling, reducering, forbedring eller lindring af sygdomme i det bageste øjensegment
AR049955A1 (es) Composiciones y metodos para el tratamiento de trastornos metabolicos
MXPA05004110A (es) Composiciones y metodos para terapia de oxibutinina transdermica.
NO20064848L (no) Imidazolforbindelser
MX2009009624A (es) Droxidopa y composicion farmaceutica de la misma para el tratamiento de la fibromialgia.
UA90668C2 (ru) Состав для лечения хронической венозной недостаточности, который содержит водный экстракт листьев красного винограда и противовоспалительное средство
BRPI0517481A (pt) método para tratar, controlar ou evitar uma doença ou distúrbio parasìtico protozoário, e, composição farmacêutica
BR0308290A (pt) Tratamento e prevenção de distúrbios inflamatórios
PL363218A1 (en) Compositions for delivery of a cortisol antagonist
MX2010005210A (es) Formulacion de aceite de oliva para alivio del dolor.
AR066916A1 (es) Anticuerpos conra c3b y metodos para la prevenc ion y el tratamiento de trastornos asociados con el complemento. composicion farmaceutica.
WO2005074536A3 (en) Compositions and methods using proton pump inhibitors
MX366119B (es) Uso de un agente inhibidor de masp-2 para el tratamiento de condiciones renales mediadas por complemento dependiente de la masp-2.
BRPI0507189A (pt) uso combinado de um agonista de glp-1 e compostos de gastrina
BRPI0408902A (pt) composições de inibidores seletivos da ciclooxigenase-2 e agonistas de 5-ht 1b/1d para o tratamento e a prevenção de enxaqueca
HK1121936A1 (en) Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
CL2008002429A1 (es) Compuestos derivados de n-bencil, n'-arilcarbonilpiperazina, con actividad agonista de los receptores x del higado (lxrs); composicion farmaceutica que los contiene; y el uso de los compuestos en el tratamiento de la aterosclerosis.
WO2008005686A8 (en) Compositions comprising a dissociated glucocorticoid receptor agonist and an immunosuppressive agent for treating dry eye
ATE549022T1 (de) Behandlung von infektionen und deren folgeleiden mit kombinierten dissoziierten glocucorticoid- rezeptor-agonisten und antiinfektionswirkstoffen
EA200800766A1 (ru) Ингибиторы pi3k для лечения эндометриоза
MX2009002228A (es) Composiciones y metodos para tratar o prevenir glaucoma o el avance del mismo.
DK2061444T3 (da) Sammensætninger og fremgangsmåder til behandling, kontrol, reducering, forbedring eller forebyggelse af allergi
HK1141249A1 (en) Compositions comprising a dissociated glucocorticoid receptor agonist for treating or controlling anterior-segment inflammation
MX2013014518A (es) Composiciones y metodos para tratar, controlar, reducir, o mejorar el dolor inflamatorio.
TW200738247A (en) Method and composition for treating allergic diseases